<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790292</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MS 20/2020</org_study_id>
    <nct_id>NCT04790292</nct_id>
  </id_info>
  <brief_title>Impact of Dexamethasone Added to Intra-articular Morphine and Bupivacaine for Post-operative Analgesia After Knee Arthroscopy</brief_title>
  <official_title>Impact of Dexamethasone Added to Intra-articular Morphine and Bupivacaine for Post-operative Analgesia After Knee Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blinded clinical trial was carried out on 40 patients undergoing knee&#xD;
      arthroscopy. Patients were divided randomly into two equal groups. All drugs used were&#xD;
      injected intra-articularly at the end of arthroscopy. In the control group, patients were&#xD;
      administered 10mg morphine added to bupivacaine 25mg. In the study group, patients were&#xD;
      administered 10mg morphine and 8mg dexamethasone added to bupivacaine 25mg. Visual analog&#xD;
      score for pain at rest and movement, time to first analgesic request, total analgesic&#xD;
      consumption, duration of analgesia and adverse effects were recorded.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analogue score(VAS) at rest and movement</measure>
    <time_frame>first 24 hours post operative</time_frame>
    <description>visual analogue score(VAS) will be used to measure pain score (VAS score 0 cm= no pain, VAS score 10 cm = worst possible pain) when the patient is fully conscious (0) and at 2, 4, 6, 8, 10, 12, 18, 24 hours post-operatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue analgesia time</measure>
    <time_frame>first 24 hours post operative</time_frame>
    <description>Time to first analgesia requirement (considering the extubation is zero time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total analgesic consumption</measure>
    <time_frame>first 24 hours post operative</time_frame>
    <description>intramuscular diclofenac sodium 75mg will be given as rescue analgesic when VAS â‰¥ 4. Total diclofenac consumption will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>group M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group M 10mg morphine +0.25% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group MD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group MD 10mg morphine + 8mg dexamethasone +0.25% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group M</intervention_name>
    <description>10mg morphine in 5ml normal saline + 10ml of 0.25% bupivacaine ( total volume 15 ml) were injected intra-articularly</description>
    <arm_group_label>group M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group MD</intervention_name>
    <description>10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly</description>
    <arm_group_label>group MD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Minimum Age: 18 years Maximum Age: 65 years Sex: Both Gender Based: No Accepts Healthy&#xD;
        Volunteers: No&#xD;
&#xD;
        Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status I and II&#xD;
&#xD;
          -  Scheduled for minor arthroscopic knee surgeries (meniscectomy, chondroplasty, minor&#xD;
             ligament repair and diagnostic arthroscopy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status above (II)&#xD;
&#xD;
          -  Undergoing major knee surgeries&#xD;
&#xD;
          -  History of allergies to any of the used drugs&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  Contraindications of morphine use (e.g. asthmatic patient, chronic obstructive&#xD;
             pulmonary disease, and addiction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heba F Abd El-Aziz Toulan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Heba Fouad Abd El-Aziz Toulan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dexamethasone</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Morphine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

